ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
First Patient Dosed in Trial of LNS8801, KEYTRUDA Combination in Advanced Cancer
October 19, 2020Linnaeus Therapeutics has dosed the first patient in its phase 1/2 adaptive-design clinical trial of its lead-product-candidate, LNS8801, in combination with KEYTRUDA® (pembrolizumab) in patients who had previous clinical benefit from immune checkpoint...
Pharma Sources Insight January 2025
